一项研究 Ocrelizumab 治疗对多发性硬化症 (MS) 参与者神经丝轻链 (NfL) 水平和参与者满意度的影响 (SurfSubQ)
一项前瞻性纵向多中心观察研究,旨在调查多发性硬化症患者皮下注射 Ocrelizumab 后的神经丝轻链水平和患者满意度
The main purpose of the study is to evaluate participant satisfaction after administration of ocrelizumab subcutaneously (SC) after 12 months using the therapy administration satisfaction questionnaire subcutaneous (TASQ-SC).
研究概览
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Reference Study ID Number: ML45551 https://forpatients.roche.com/ No attachments to email below
- 电话号码:888-662-6728 (U.S. Only)
- 邮箱:global-roche-genentech-trials@gene.com
研究联系人备份
- 姓名:Fastest response: use the inquiry form https://www.gene.com/contact-us/submit-medical-inquiry
学习地点
-
-
-
Aachen、德国、52074
- 招聘中
- Uniklinik RWTH Aachen
-
Amberg、德国、92224
- 招聘中
- Gesundheitszentrum St. Marien GmbH
-
Arnsdorf、德国、01477
- 招聘中
- Sächsisches Krankenhaus Arnsdorf
-
Aschaffenburg、德国、63739
- 招聘中
- Neuropraxis im Stadtpalais Dres. Ulzheimer/Herröder/Wessig GbR
-
Bad Soden、德国、65812
- 招聘中
- Neurologie Bad Soden
-
Bamberg、德国、96052
- 招聘中
- Neurologische Praxis - Kallmann Neurologie - mszb
-
Berg、德国、82335
- 撤销
- Marianne-Strauß-klinik
-
Berlin、德国、13347
- 招聘中
- Jüdisches Krankenhaus Berlin
-
Berlin、德国、12099
- 招聘中
- NEUROZENTRUM tempelhof.berlin
-
Berlin、德国、10713
- 招聘中
- Neurologisches Facharztzentrum Berlin am Sankt Gertrauden-Krankenhaus
-
Berlin、德国、12099
- 招聘中
- Praxis Dr. Said Masri
-
Berlin、德国、14169
- 招聘中
- NeuroZentrum Zehlendorf Dr. Ringel und Dr. Scherer
-
Berlin、德国、14195
- 招聘中
- Neurologisches Zentrum für Bewegungsstörungen und Diagnostik
-
Bochum、德国、44791
- 招聘中
- St. Josef-Hospital
-
Bogen、德国、94327
- 招聘中
- Dres. Lippert/Kausch
-
Buchholz、德国、21244
- 撤销
- Krankenhaus Buchholz Abt. Neurologie
-
Celle、德国、29223
- 招聘中
- Neuropraxis Celle: Praxis für Neurologie & Psychatrie
-
Celle、德国、29223
- 招聘中
- Allgemeines Krankenhaus Celle / Klinik für Neurologie
-
Chemnitz、德国、09117
- 主动,不招人
- Praxisgemeinschaft Dres. Sylke Domke und Vasil Gjaurov
-
Cologne、德国、50935
- 招聘中
- NeuroMed Campus Neurologische Gemeinschaftspraxis am St. Elisabeth Krankenhaus
-
Dortmund、德国、44137
- 撤销
- Gemeinschaftspraxis Dr. med. Josef Leclaire und Dr. med. Thomas Rotermund
-
Düsseldorf、德国、40225
- 招聘中
- Universitätsklinikum Düsseldorf
-
Düsseldorf、德国、40211
- 招聘中
- Gemeinschaftspraxis für Neurologie
-
Düsseldorf、德国、40625
- 撤销
- Nervenarztpraxis Gerresheim
-
Eltville、德国、65343
- 招聘中
- Gemeinschaftspraxis für Neurologie und Psychiatrie, Psychotherapie
-
Erbach/Odenwald、德国、64711
- 招聘中
- NeuroCentrum Odenwald
-
Erlangen、德国、91054
- 招聘中
- Universitätsklinikum Erlangen, Neurologische Klinik
-
Essen、德国、45138
- 招聘中
- Zentrum für ambulante Neurologie / Praxis Knorn Landefeld Friedrich
-
Essen、德国、45257
- 招聘中
- Praxis Nervenstark
-
Forchheim、德国、91301
- 完全的
- Praxis für Neurologie, Nervenheilkunde & Neurochirurgie
-
Frankfurt、德国、65929
- 招聘中
- Varisano Klinikum Frankfurt Höchst GmbH
-
Frankfurt、德国、60528
- 招聘中
- Klinikum Joh.Wolfg.Goethe-UNI Senckenbergisches Institut für Neuroonkologie
-
Freiburg im Breisgau、德国、79106
- 招聘中
- Universitätsklinikum Freiburg, Klinik für Neurologie und Neurophysiologie
-
Füssen、德国、87629
- 招聘中
- Praxis im Bahnhof
-
Giessen、德国、35392
- 招聘中
- Universitätsklinikum Gießen und Marburg GmbH
-
Gladenbach、德国、35075
- 招聘中
- Neurologie & Psychiatrie Gladenbach - MS-Zentrum
-
Günzburg、德国、89312
- 招聘中
- MVZ Bezirkskliniken Schwaben, Standort Günzburg
-
Halle、德国、06120
- 招聘中
- Krankenhaus Martha-Maria Halle-Doelau
-
Hamburg、德国、20249
- 招聘中
- Neurologische Praxis Eppendorf
-
Hamburg、德国、20246
- 招聘中
- Universiätsklinikum Hamburg-Eppendorf
-
Hanover、德国、30171
- 招聘中
- Neurologische Praxis
-
Hennigsdorf、德国、16761
- 招聘中
- Oberhavel Kliniken GmbH, Klinik Hennigsdorf, Neurologie
-
Herford、德国、32052
- 招聘中
- Praxis Dr. Hospely
-
Hettingen、德国、72513
- 招聘中
- Haus- und Facharztzentrum Laucherttal / Alb
-
Ibbenbueren、德国、49477
- 招聘中
- Klinikum Ibbenbüren gmbH
-
Isselburg、德国、46419
- 招聘中
- Augustahospital Anholt;Neurologie
-
Jena、德国、07747
- 招聘中
- Universitätsklinikum Jena, Klinik für Neurologie
-
Kiel、德国、24105
- 招聘中
- Uniklinik Schleswig-Holstein
-
Leipzig、德国、04315
- 招聘中
- Neurologische Praxis Dr. Ehrlich
-
Leipzig、德国、04299
- 招聘中
- Arztpraxis Dr. med. Torsten Sühnel
-
Lübeck、德国、23538
- 招聘中
- Universitätsklinik Schleswig Holstein, Campus Lübeck
-
Magdeburg、德国、39120
- 招聘中
- Universitätsklinikum Magdeburg
-
Magdeburg、德国、39104
- 招聘中
- Neurologie im Ulrichshaus Magdeburg
-
Mannheim、德国、68167
- 招聘中
- Universitätsklinikum Mannheim
-
Mannheim、德国、68163
- 招聘中
- Neuroplus Dres. Lennart Thilmann/ Patrick Thilmann
-
Marburg、德国、35043
- 招聘中
- Universitätsklinikum Giessen und Marburg
-
Meerbusch、德国、40667
- 招聘中
- Praxis Dr. Leussink
-
Minden、德国、32423
- 招聘中
- Neurologie am Preußenmuseum
-
München、德国、81675
- 招聘中
- Praxis für Neurologie und Psychiatrie am Prinzregentenplatz
-
München、德国、80939
- 招聘中
- Neurologie München Nord
-
München、德国、81675
- 招聘中
- Klinikum rechts der Isar der TU München
-
Münster、德国、48149
- 招聘中
- Universitätsklinikum Münster
-
Münster、德国、48165
- 招聘中
- Herz-Jesu-Krankenhaus Hiltrup GmbH
-
Neu-Ulm、德国、89231
- 招聘中
- Neurologisch-psychiatrische Praxis im A4
-
Neuburg am Inn、德国、86633
- 招聘中
- Praxis Dr. med. Bergmann
-
Neuruppin、德国、16816
- 招聘中
- Ruppiner Kliniken, Hochschulklinikum der Medizinischen Hochschule Brandenburg, Klinik für Neurologie
-
Nuremberg、德国、90451
- 招聘中
- Neurologie Nürnberg-Eibach
-
Nuremberg、德国、90419
- 招聘中
- Gemeinschaftspraxis Uhlig und Windsheimer
-
Osnabrück、德国、49074
- 撤销
- Neurologie an der Hase
-
Pforzheim、德国、75172
- 招聘中
- Facharztpraxis für Neurologie und Psychiatrie Dres Mattes/Stockert
-
Quakenbrück、德国、49610
- 招聘中
- Neurologisches Studienzentrum Artland
-
Regensburg、德国、93059
- 招聘中
- Gemeinschaftspraxis für Neurologie
-
Remscheid、德国、42853
- 招聘中
- Gemeinschaftspraxis Dr. Stienker-Fisse & Dr. Fisse
-
Rülzheim、德国、76761
- 招聘中
- ZNS Südpfalz
-
Schwetzingen、德国、68723
- 招聘中
- Neurologische Praxis Dr. Wagner
-
Siegen、德国、57076
- 招聘中
- Praxis für Neurologie und Psychiatrie
-
Siegen、德国、57072
- 招聘中
- Gemeinschaftspraxis für Neurologie, Psychiatrie und Psychotherapie
-
Singen、德国、78224
- 招聘中
- EMSA - Zentrum für Neurologie?/?Psychiatrie?/?Neuroradiologie
-
Sinsheim、德国、74889
- 招聘中
- Praxis Dr. med. Max Deist und Michael Ernst ?Sinsheim
-
Steglitz、德国、12163
- 招聘中
- Gemeinschaftspraxis Dr. Wolfram von Pannwitz, MBA & Dr. med. Marie Perle Brinckmann
-
Stuttgart、德国、70174
- 招聘中
- Praxis Dr. med. Andreas Kowalik, Arzt für Neurologie und Psychiatrie
-
Stuttgart、德国、70176
- 招聘中
- Neuropraxis Sotiriadis
-
Stuttgart、德国、70178
- 招聘中
- Neurozentrum Stuttgart Mitte Sophienstraße
-
Sundern、德国、59846
- 招聘中
- Sauerlandklinik Hachen
-
Tübingen、德国、72076
- 招聘中
- Universitätsklinikum Tübingen, Zentrum für Neurologie
-
Ulm、德国、89078
- 招聘中
- Nervenfachaerztliche Gemeinschaftspraxis Ulm
-
Unterhaching、德国、82008
- 招聘中
- Neuropraxis München Süd
-
Weil der Stadt、德国、71263
- 招聘中
- Praxis für Neurologie, Psychiatrie und Epileptologie
-
Wolfratshausen、德国、82515
- 招聘中
- Praxis Dr. Michaela Krause
-
Zwickau、德国、08060
- 招聘中
- Heinrich-Braun-Krankenhaus Städtisches Klinikum
-
Öhringen、德国、74613
- 招聘中
- Dres. Beckmann / Schlüter
-
-
-
-
-
Bern、瑞士、3010
- 招聘中
- Inselspital-Universitaetsspital Bern
-
Zurich、瑞士、8001
- 招聘中
- Bellevue Medical Grop AG
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Participants with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), diagnosed according to McDonald criteria of 2017 or revised McDonald criteria 2024, and treated with ocrelizumab SC for the first time during routine clinical practice will be observed in this study.
描述
Inclusion Criteria:
- Diagnosis of MS
- RMS and PPMS participants diagnosed according to the McDonald criteria of 2017 or revised McDonald criteria 2024
- First treatment during the course of MS therapy with ocrelizumab SC according to the local prescribing information, regardless of the reason for starting treatment with ocrelizumab
Exclusion Criteria:
- Participation in interventional studies investigating DMTs for MS
- Prior or simultaneous participation in CONFIDENCE or MoOzaRt (ISRCTN55332718) non interventional study (NIS) at the same study site
- Prior treatment with rituximab (MabThera®) or ublituximab (Briumvi®)
- Severe psychiatric disability
- Pregnant women
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Ocrelizumab
Participants who are receiving ocrelizumab, SC injection, for the first time as part of their routine MS therapy at physician's discretion in accordance with local clinical practice and/or labeling will be observed for treatment satisfaction with SC injection for up to 12 months. |
Ocrelizumab will be administered as SC injection as per discretion of the treating physician in accordance with local clinical practice and local labeling.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Participants by Their Level of Satisfaction With Ocrelizumab SC After 12 Months Assessed Using TASQ-SC
大体时间:Month 12
|
TASQ-SC is a 12-item, participant-reported questionnaire measuring the impact of treatment administration on five domains: Physical Impact, Psychological Impact, Impact on Activities of Daily Living, Convenience, and Satisfaction. Each of the domain/scale scores is scored on a scale of 1-100, where higher scores indicate higher overall satisfaction with the therapy. |
Month 12
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
血清中 NfL 蛋白水平的浓度
大体时间:基线、第 6 个月、第 12 个月
|
基线、第 6 个月、第 12 个月
|
|
|
由医生调查评估的参与者数量(按对 Ocrelizumab SC 的满意度划分)
大体时间:基线、第 6 个月、第 12 个月
|
基线、第 6 个月、第 12 个月
|
|
|
年化复发率
大体时间:第 12 个月
|
第 12 个月
|
|
|
进展独立于复发活动 (PIRA) 的参与者百分比
大体时间:直至第 12 个月
|
直至第 12 个月
|
|
|
发生非严重不良事件 (nsAE)、严重不良事件 (SAE) 和特殊利益不良事件 (AESI) 的参与者人数
大体时间:直至第 12 个月
|
直至第 12 个月
|
|
|
Change From Baseline in NfL Protein Levels in Serum
大体时间:Baseline, Month 6, Month 12
|
Baseline, Month 6, Month 12
|
|
|
Number of Participants by Their Level of Satisfaction With Ocrelizumab SC After the First Injection and After 6 Months Assessed Using TASQ-SC
大体时间:Baseline, Month 6
|
TASQ-SC is a 12-item, participant-reported questionnaire measuring the impact of treatment administration on five domains: Physical Impact, Psychological Impact, Impact on Activities of Daily Living, Convenience, and Satisfaction. Each of the domain/scale scores is scored on a scale of 1-100, where higher scores indicate higher overall satisfaction with the therapy. |
Baseline, Month 6
|
|
Correlation Between NfL Protein Levels in Serum With MS Relapse
大体时间:Up to Month 12
|
The changes in levels of NfL protein levels in serum and its correlation with MS relapse will be analyzed using Pearson or Spearman correlation coefficients. |
Up to Month 12
|
|
Correlation Between NfL Protein Levels in Serum With Expanded Disability Status Scale (EDSS)
大体时间:Up to Month 12
|
The changes in levels of NfL protein levels in serum and its correlation with EDSS will be analyzed using Pearson or Spearman correlation coefficients. EDSS is a scale for assessing neurologic impairment in MS. Values are from 0 points (normal neurological examination) up to 10 points (death), increasing in increments of 0.5 points. Higher scores represent increased disability. |
Up to Month 12
|
|
Correlation Between NfL Protein Levels in Serum With Previous MS Disease Modifying Therapy (DMT)
大体时间:Up to Month 12
|
The changes in levels of NfL protein in serum and its correlation with DMT will be analyzed using Pearson or Spearman correlation coefficients. |
Up to Month 12
|
|
Correlation Between NfL Protein Levels in Serum With NfL Confounder - Serum Creatinine
大体时间:Up to Month 12
|
The changes in levels of NfL protein in serum and its correlation with serum creatinine will be analyzed using Pearson or Spearman correlation coefficients. |
Up to Month 12
|
|
Correlation Between NfL Protein Levels in Serum With NfL Confounder - Co-morbidities
大体时间:Up to Month 12
|
The changes in levels of NfL protein in serum and its correlation with co-morbidities will be analyzed using Pearson or Spearman correlation coefficients. |
Up to Month 12
|
|
Correlation Between NfL Protein Levels in Serum With NfL Confounder - Age
大体时间:Up to Month 12
|
The changes in levels of NfL protein in serum and its correlation with age will be analyzed using Pearson or Spearman correlation coefficients. |
Up to Month 12
|
|
Correlation Between NfL Protein Levels in Serum With NfL Confounder - Body Mass Index [BMI]
大体时间:Up to Month 12
|
The changes in levels of NfL protein in serum and its correlation with BMI will be analyzed using Pearson or Spearman correlation coefficients. |
Up to Month 12
|
|
Correlation Between NfL Protein Levels in Serum With Magnetic Resonance Imaging (MRI) Lesion Count
大体时间:Up to Month 12
|
The changes in levels of NfL protein in serum and its correlation with MRI lesion count will be analyzed using Pearson or Spearman correlation coefficients. |
Up to Month 12
|
|
Correlation Between NfL Protein Levels in Serum With Glial Fibrillary Acidic Protein (GFAP) Levels
大体时间:Up to Month 12
|
The changes in levels of NfL protein in serum and its correlation with GFAP levels will be analyzed using Pearson or Spearman correlation coefficients. |
Up to Month 12
|
|
Correlation Between NfL Protein Levels in Serum With No Evidence of Disease Activity-3 (NEDA-3)
大体时间:Up to Month 12
|
NEDA-3 is defined by no confirmed MS relapse, no new or enlarging T2 lesions, no Gadolinium-positive T1 lesions, and no six-month confirmed disability worsening. The changes in levels of NfL protein in serum and its correlation with NEDA-3 will be analyzed using Pearson or Spearman correlation coefficients. |
Up to Month 12
|
|
Change From Baseline in Participant Satisfaction With Ocrelizumab SC Assessed Using Treatment Satisfaction Questionnaire for Medication (TSQM) 1.4
大体时间:Baseline, Month 6, Month 12
|
TSQM version 1.4 is a 14-item questionnaire used to measure level of satisfaction or dissatisfaction with the medication on 4 domains: Effectiveness, Side Effects, Convenience, and Global Satisfaction. Each of the domain is scored on likert-type scales of 5 or 7 points ranging from 1 (least satisfied) to 5 or 7 (most satisfied). Item scores are summarized to give four domain scores, which are in turn transformed to a scale of 0-100. Higher scores indicate higher overall satisfaction with the therapy. |
Baseline, Month 6, Month 12
|
合作者和调查者
调查人员
- 研究主任:Clinical Trials、Hoffmann-La Roche
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- ML45551
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.